Pathway to the clinic: inhibition of P38 MAP kinase. A review of ten chemotypes selected for development
about
Modulation of host cell signaling pathways as a therapeutic approach in periodontal diseaseA p38 substrate-specific MK2-EGFP translocation assay for identification and validation of new p38 inhibitors in living cells: a comprising alternative for acquisition of cellular p38 inhibition dataSkepinone-L is a selective p38 mitogen-activated protein kinase inhibitorImpeding the interaction between Nur77 and p38 reduces LPS-induced inflammationInhibition of p38 MAPK suppresses inflammatory cytokine induction by etoposide, 5-fluorouracil, and doxorubicin without affecting tumoricidal activityThe p38alpha mitogen-activated protein kinase as a central nervous system drug discovery target.Two additive mechanisms impair the differentiation of 'substrate-selective' p38 inhibitors from classical p38 inhibitors in vitro.Chiral kinase inhibitors.Virtual screening using a conformationally flexible target protein: models for ligand binding to p38α MAPK.Basic tetrapeptides as potent intracellular inhibitors of type A botulinum neurotoxin protease activity.Novel Aeruginosin-865 from Nostoc sp. as a potent anti-inflammatory agent.Angiotensin II upregulates endothelial lipase expression via the NF-kappa B and MAPK signaling pathways.The anti-tumor efficacy of 2-deoxyglucose and D-allose are enhanced with p38 inhibition in pancreatic and ovarian cell lines.The effect of RO3201195 and a pyrazolyl ketone P38 MAPK inhibitor library on the proliferation of Werner syndrome cells.p38 pathway kinases as anti-inflammatory drug targets.Multiple effects of acetaminophen and p38 inhibitors: towards pathway toxicology.High-throughput kinase profiling as a platform for drug discovery.The Opposite Expected Effect of p38 Inhibitors on Fat Graft Survival.Allium sativum Compared to Cilostazol as an Inhibitor of Myointimal HyperplasiaDevelopment of small-molecule therapies for autoimmune diseases.p38α mitogen-activated protein kinase inhibitors, a patent review (2005-2011).Critical review of p38 MAP kinase inhibitors: a bioanalytical perspective.Mitogen-activated protein kinases as therapeutic targets for rheumatoid arthritis.Taming inflammation by targeting cytokine signaling: new perspectives in the induction of transplantation tolerance.Signalling and targeted therapy of inflammatory cells in epidermolysis bullosa acquisita.First comprehensive structural and biophysical analysis of MAPK13 inhibitors targeting DFG-in and DFG-out binding modes.IL-1β-induced and p38MAPK-dependent activation of the mitogen-activated protein kinase-activated protein kinase 2 (MK2) in hepatocytes: Signal transduction with robust and concentration-independent signal amplification.Use of p38 MAPK Inhibitors for the Treatment of Werner Syndrome.The toxicity mechanisms of action of Aβ25-35 in isolated rat cardiac myocytes.Synthesis of the highly selective p38 MAPK inhibitor UR-13756 for possible therapeutic use in Werner syndrome.Gram-scale synthesis of the p38α MAPK-inhibitor VX-745 for preclinical studies into Werner syndrome.Anti-inflammatory properties of mutolide isolated from the fungus Lepidosphaeria species (PM0651419).A proof-of-concept and drug-drug interaction study of pamapimod, a novel p38 MAP kinase inhibitor, with methotrexate in patients with rheumatoid arthritis.Mechanism of TiO2 nanoparticle-induced neurotoxicity in zebrafish (Danio rerio).Effects of p38 MAP kinase inhibitors on the differentiation and maturation of erythroid progenitors.Effects of Tianxiangdan Granule treatment on atherosclerosis via NF‑κB and p38 MAPK signaling pathways.Differential effect of p38 and MK2 kinase inhibitors on the inflammatory and toxicity biomarkers in vitro.
P2860
Q26852727-6CB31753-5817-4DF8-AF4F-0EA58AD1DCFDQ27335745-6D44F13A-5134-4F76-8AEF-24F2A6C6EBF2Q27676453-DE7F9F57-EAD6-4BCE-AA16-48048C61FE01Q27700060-8D531910-523D-41B5-9D9F-92F6CAC71DC4Q28472865-2D6993FE-9F7D-4AF1-B2B2-86CD3F845973Q33393902-9E325DE0-CF95-456D-AE19-41EDD81194E6Q33540867-FC2405EE-F9B7-431D-B4C6-8555E2CC5CFEQ33811207-19C8E418-BDD5-4A57-B533-6EB07E7B34B7Q34243088-2B4CC152-CC2F-43E8-8054-34A8065745EDQ34503077-95EA4BBB-54E9-4617-91F7-8E5B9F258D15Q35016667-67BE8F9A-C554-48C2-95D3-C0100B4CDA4FQ35273462-AB247434-A35E-47C1-8117-20007F4F5365Q35339214-C6F6714A-C13A-475A-BF7B-6301828CD49EQ35854103-F0EF0113-87AD-4ED6-8D52-441466976386Q36919718-FACB0E25-4A74-47F3-9558-625328FCADD0Q37087520-B68C6C19-6640-41A9-8AC1-9D71594C8B03Q37135359-EB72EA73-55B7-463B-8ECA-C2C316870E27Q37158987-C9A28459-7211-48E7-ABFE-6A6D11F52B4CQ37391580-7C2CBE49-791C-4FE2-8BCF-61EA5C7F3078Q37730104-A9374F33-C5C7-4DDE-B33A-DBDA8DE6ADDBQ37955936-82A67F6B-CD7C-4F86-B1D6-66B091D3CB0AQ37970731-0C3605C4-C8F5-4146-9903-AB0FBF561F9DQ38078271-B3EBB3E3-6B85-43CE-97FE-7D0C9DE19462Q38217596-1AB2FE3F-502D-4C73-94EA-19846002DCBAQ38749755-3E5EF261-BC3A-47D5-817A-8919C19C93B2Q38846155-DF710667-6741-4A6C-B452-227A3743A867Q38949321-84F830AC-C938-4890-B286-ACF4F083D68CQ38974348-E5CDCB2F-97CE-4FE3-8C4F-75D61A4957CDQ39144999-85206184-B8CD-42C6-9162-C71CB675BB79Q39572401-5E967FD5-5AB0-4B07-A4D2-8BBCBD30FCC4Q39769285-DA37107D-2060-4B01-BD37-1938664491F9Q43164008-D57586FE-7041-4C6B-8DBC-757833E0F5FBQ43184375-036BA9AE-BD86-477B-9458-BF28151B84F3Q43845642-7B8739EB-393E-4C1B-B90B-E312A279A641Q46173371-81B634C4-A56A-4E83-A295-8E8061703F96Q47276537-047F0297-988B-4607-A392-4ED488D10213Q48752249-3E3ACB33-030C-456D-AF69-9D4BFEA7D850
P2860
Pathway to the clinic: inhibition of P38 MAP kinase. A review of ten chemotypes selected for development
description
2005 nî lūn-bûn
@nan
2005 թուականին հրատարակուած գիտական յօդուած
@hyw
2005 թվականին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Pathway to the clinic: inhibit ...... types selected for development
@ast
Pathway to the clinic: inhibit ...... types selected for development
@en
Pathway to the clinic: inhibit ...... types selected for development
@nl
type
label
Pathway to the clinic: inhibit ...... types selected for development
@ast
Pathway to the clinic: inhibit ...... types selected for development
@en
Pathway to the clinic: inhibit ...... types selected for development
@nl
prefLabel
Pathway to the clinic: inhibit ...... types selected for development
@ast
Pathway to the clinic: inhibit ...... types selected for development
@en
Pathway to the clinic: inhibit ...... types selected for development
@nl
P3181
P356
P1476
Pathway to the clinic: inhibit ...... types selected for development
@en
P2093
David M Goldstein
Tobias Gabriel
P304
P3181
P356
10.2174/1568026054985939
P407
P577
2005-01-01T00:00:00Z